等级
pharmaceutical primary standard
API类
lithocholic acid
制造商/商品名称
EDQM
mp
183-188 °C (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
[H][C@]12CC[C@@]3([H])[C@]4([H])CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)CC[C@]3([H])[C@@]1(C)CC[C@@H](O)C2
InChI
1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
InChI key
SMEROWZSTRWXGI-HVATVPOCSA-N
正在寻找类似产品? 访问 产品对比指南
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Nathalie Ménard et al.
Pharmaceutical research, 29(7), 1882-1896 (2012-03-28)
Novel surfactants made of diglutamic acid (DG) polar head linked to lithocholic, arachidonic, linoleic or stearic acids were designed for drug solubilization. Surfactants 3-D conformer and packing parameter were determined by molecular modelling and self-assembling properties by pyrene fluorescence measurements.
Tanmay Bera et al.
Langmuir : the ACS journal of surfaces and colloids, 29(1), 387-392 (2012-12-21)
The concentration level of bile acids is a clinical biomarker for the diagnosis of intestinal diseases because individuals suffering from intestinal diseases have a sharply increased concentration of bile acids at micromolar levels. Here, we report the detection of lithocholic
Benjamin L Woolbright et al.
Toxicology letters, 228(1), 56-66 (2014-04-20)
Lithocholic acid (LCA) supplementation in the diet results in intrahepatic cholestasis and bile infarcts. Previously we showed that an innate immune response is critical for cholestatic liver injury in the bile duct ligated mice. Thus, the purpose of this study
Alan F Hofmann
Drug metabolism reviews, 36(3-4), 703-722 (2004-11-24)
Lithocholic acid, a monohydroxy, secondary bile acid, is formed by bacterial 7-dehydroxylation of the primary bile acid chenodeoxycholic acid (CDCA) and of the secondary bile acid ursodeoxycholic acid (UDCA). Lithocholic acid and its precursor CDCA are toxic when fed to
Simon M Vogel et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(42), 16906-16910 (2012-10-05)
The proteins MDM2 and MDM4 are key negative regulators of the tumor suppressor protein p53, which are frequently upregulated in cancer cells. They inhibit the transactivation activity of p53 by binding separately or in concert to its transactivation domain. MDM2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持